This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Daniely, M. Articles by Friedman, E. Search for Related Content PubMed PubMed Citation Articles by Daniely, M. Articles by Friedman, E.

Comparative Genomic Hybridization Analysis of Nonfunctioning Pituitary Tumors¹

The Institute of Genetics (M.D., A.A., G.B., B.G., E.F.) and the Oncogenetics Unit (E.F.) Chaim Sheba Medical Center, Tel-Hashomer, Israel; and the Department of Neurosurgery, Kopfklinikum (E.F.A., M.B., R.F.), Erlangen, Germany

Address all correspondence and requests for reprints to: Eitan Friedman, M.D., Ph.D., The Suzanne Levy Gertner Oncogenetics Laboratory, Institute of Genetics, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel. E-mail: feitan@post.tau.ac.il, or eitan211{at}netvision.net.il

Clinically nonfunctioning pituitary adenomas constitute about one third of pituitary neoplasms and are considered monoclonal tumors. The molecular mechanisms of tumorigenesis in these neoplasms are poorly understood, as evidenced by the paucity of reported somatic genetic alterations. Furthermore, the somatic mutations detected to date were primarily ascribed to candidate genes or chromosomal regions: gsp, ras, p53 mutations, and allelic losses of 11q and 13q. To gain insight into which chromosomal regions bear genes involved in nonfunctioning pituitary tumorigenesis, we examined 23 such tumors by comparative genomic hybridization. Four tumors showed no genetic abnormality, and the rest (17 of 23, 74%) exhibited at least one chromosomal region of abnormality. Gains and losses affected all chromosomes (except for chromosome 14). Notably, 8 of 23 tumors (34.7%) displayed sex chromosome and chromosome 18 aberrations (amplifications or deletions). Nonrandom DNA amplification of subchromosomal regions on 4q, 5q (5q135q23), 9p (9p219pter), 13q (13q2113q32), and 17q were detected in 10–30% of the tumors. Noteworthy, no tumor displayed deletion of 11q, the MEN1 gene locus. These findings suggest that genes localized to previously undescribed chromosomal regions play a role in the tumorigenesis of nonfunctioning pituitary adenomas.

This article has been cited by other articles:

				A. Abu, M. Frydman, D. Marek, E. Pras, C. Stolovitch, A. Aviram-Goldring, S. Rienstein, H. Reznik-Wolf, and E. Pras Mapping of a Gene Causing Brittle Cornea Syndrome in Tunisian Jews to 16q24 Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5283 - 5287. [Abstract] [Full Text] [PDF]

				W E Farrell Pituitary tumours: findings from whole genome analyses. Endocr. Relat. Cancer, September 1, 2006; 13(3): 707 - 716. [Abstract] [Full Text] [PDF]

				P. Vigano, E. Somigliana, I. Chiodo, A. Abbiati, and P. Vercellini Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis Hum. Reprod. Update, January 1, 2006; 12(1): 77 - 89. [Abstract] [Full Text] [PDF]

				J. Zhao, D. Dahle, Y. Zhou, X. Zhang, and A. Klibanski Hypermethylation of the Promoter Region Is Associated with the Loss of MEG3 Gene Expression in Human Pituitary Tumors J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2179 - 2186. [Abstract] [Full Text] [PDF]

				S. Ezzat Pituitary Tumor Pathogenesis--The Hunt for Novel Candidate Genes Continues J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5116 - 5118. [Full Text] [PDF]

				J. Gogusev, J. B. de Joliniere, L. Telvi, M. Doussau, A. Stojkoski, and M. Levradon Cellular and Genetic Constitution of Human Endometriosis Tissues Reproductive Sciences, March 1, 2000; 7(2): 79 - 87. [Abstract] [PDF]